The company announced a breakthrough in scalable, on-chip cryogenic control for gate-model qubits, demonstrating technical progress. It signed multiple customer deals in Q3 across airlines, banking, and pharma, lifting bookings to $2.4 million and highlighting growing commercial adoption. An analyst maintained a Buy rating on the stock. However, a competitor, IonQ, was noted to be moving ahead in areas like gate fidelity and revenue momentum.